Knight Therapeutics Inc
(GUD.TO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 95,573 | 86,604 | 74,197 | 81,500 | 89,905 |
| Cost of Goods | 48,236 | 44,905 | 39,982 | 41,318 | 52,412 |
| Gross Profit | 47,337 | 41,699 | 34,215 | 40,182 | 37,493 |
| Operating Expenses | 42,843 | 39,039 | 34,298 | 39,252 | 37,603 |
| Operating Income | 4,494 | 2,660 | -83 | 930 | -110 |
| Interest Expense | 2,284 | 2,577 | 4,090 | 2,603 | 3,004 |
| Other Income | -1,497 | -7,227 | -21,979 | 10,571 | 3,326 |
| Pre-tax Income | 713 | -7,144 | -26,152 | 8,898 | 212 |
| Income Tax | 2,655 | -2,598 | -1,826 | -690 | -1,628 |
| Net Income Continuous | -1,942 | -4,546 | -24,326 | 9,588 | 1,840 |
| Net Income | $-1,942 | $-4,546 | $-24,326 | $9,588 | $1,840 |
| EPS Basic Total Ops | -0.02 | -0.04 | -0.23 | 0.09 | 0.02 |
| EPS Basic Continuous Ops | -0.02 | -0.04 | -0.23 | 0.09 | 0.02 |
| EPS Diluted Total Ops | -0.02 | -0.04 | -0.23 | 0.09 | 0.02 |
| EPS Diluted Continuous Ops | -0.02 | -0.04 | -0.23 | 0.09 | 0.02 |
| EBITDA(a) | $16,166 | $8,014 | $-10,604 | $25,199 | $15,374 |